

From the September 24, 2021
Florida Pharmaceutical & Therapeutics Committee Meeting
(Changes Effective October 1, 2021)

ANALGESICS, NARCOTICS LONG	PDL Status Before Meeting	PDL Status After Meeting	Comments
METHADONE CONC SYRINGE (ORAL)	NA	Non-PDL	
ANALGESICS, NARCOTICS SHORT			
QDOLO (ORAL)	NA	Non-PDL	
ANTICONVULSANTS			
ELEPSIA XR TABLET (ORAL)	NA	Non-PDL	
ANTIFUNGALS, ORAL			
NOXAFIL TABLET (ORAL)	Non-PDL	PDL	
CHEMOTHERAPY RESCUE			
COSELA (INTRAVEN)	NA	Non-PDL	
CYTOKINE AND CAM ANTAGONISTS			
SKYRIZI PEN (SUBCUTANEOUS)	NA	Non-PDL	
HYPOGLYCEMICS, SGLT2			
SYNJARDY (ORAL)	Non-PDL	PDL	
XIGDUO XR (ORAL)	Non-PDL	PDL	
LAXATIVES & CATHARTICS			
ALVIMOPAN CAPSULE (ORAL)	NA	Non-PDL	
SUTAB (ORAL)	NA	Non-PDL	
MULTIPLE SCLEROSIS AGENTS			
BAFIERTAM CAPSULE DR (ORAL)	NA	Non-PDL	
MAYZENT DOSE PACK (ORAL)	NA	Non-PDL	
PONVORY STARTER PACK (ORAL)	NA	Non-PDL	
PONVORY TABLET (ORAL)	NA	Non-PDL	
NSAIDS			
NAPROXEN SUSPENSION (AG) (ORAL)	Non-PDL	PDL	
NAPROXEN SUSPENSION (ORAL)	Non-PDL	PDL	
NSAIDS, INJECTABLE			
ANJESO (INTRAVEN)	NA	PDL	
CALDOLOR (INTRAVEN)	NA	Non-PDL	
OCTREOTIDES & RELATED			
BYNFEZIA (SUBCUTANEOUS)	NA	Non-PDL	
MYCAPSSA (ORAL)	NA	Non-PDL	
ONCOLOGY, ORAL - HEMATOLOGIC			
INQOVI (ORAL)	NA	Non-PDL	
ONUREG (ORAL)	NA	Non-PDL	
UKONIQ (ORAL)	NA	Non-PDL	
ONCOLOGY, ORAL - LUNG			
GAVRETO (ORAL)	NA	Non-PDL	
LUMAKRAS (ORAL)	NA	Non-PDL	
TEPMETKO (ORAL)	NA	Non-PDL	

ONCOLOGY, ORAL - OTHER			
TRUSELTIQ (ORAL)	NA	Non-PDL	
ONCOLOGY, ORAL - PROSTATE			
ORGOVYX (ORAL)	NA	Non-PDL	
ONCOLOGY, ORAL - RENAL CELL			
FOTIVDA (ORAL)	NA	Non-PDL	
SUTENT (ORAL)	PDL	Non-PDL	
OPHTHALMICS, ANTI-INFLAMMATORIES			
FML S.O.P. (OPHTHALMIC)	PDL	Non-PDL	
OPHTHALMICS, ANTI-INFLAMMATORY/IMMUNOMODULATOR			
EYSUVIS (OPHTHALMIC)	NA	Non-PDL	
PROGESTATIONAL AGENTS			
PROMETRIUM (ORAL)	PDL	Non-PDL	
STEROIDS, TOPICAL VERY HIGH			
CLOBETEX KIT (MISCELL)	NA	Non-PDL	
STIMULANTS AND RELATED AGENTS			
QELBREE (ORAL)	NA	Non-PDL	
UTERINE DISORDER TREATMENTS			
MYFEMBREE (ORAL)	NA	PDL	Clinical PA

NA = NOT APPLICABLE (FOR NEW PRODUCTS)